Retatrutide (GLP-3)
Retatrutide (GLP-3)
Retatrutide is a next-generation triple-agonist peptide being studied for its potential effects on weight loss and metabolic health. By targeting the GLP-1, GIP, and glucagon receptors, current research suggests it may help regulate appetite, increase energy expenditure, improve glucose metabolism, and support reductions in body fat.
This compound is widely studied in metabolic and obesity research due to its unique multi-pathway mechanism.
For laboratory research use only. Not for human consumption.
Certificate of Analysis
Third Party Tested by accredited US laboratories
| Variant | GLP-3 (RT) 10mg |
| Lot # | A1115 |
| Labeled | 10mg |
| Actual | 10.14mg |
| Tested | Feb 4, 2025 |
Frequently Researched Together
Weight management & recovery peptides
What Makes Retatrutide Different?
Unlike GLP-1 (which targets 1 receptor) or GLP-2 (which targets 2), GLP-3 activates three different hormone receptors at once. Each receptor triggers a different metabolic pathway โ and together, they deliver more powerful effects than any single-target approach.
Improves fat metabolism
Enhances satiety
Slows digestion
Improves blood sugar
Increases energy burn
Lowers cholesterol
The glucagon receptor is what sets GLP-3 apart. In trials, researchers observed that activating this receptor:
| GLP-1 | GLP-1 only |
| GLP-2 | GLP-1 + GIP |
| GLP-3 | GLP-1 + GIP + GCG |
What Researchers Observed
Latest clinical trial data
At the highest dose (12mg), here's how many participants achieved meaningful weight loss:
Researchers observed a clear dose-dependent response โ higher doses produced more weight loss.
Beyond Weight Loss
Other benefits observed in trials
Like all GLP-1 medications, participants lost some lean mass along with fat. The ratio was similar to other weight loss drugs.
Multiple markers of heart health improved during trials.
| Triglycerides | โ 38% |
| LDL Cholesterol | โ 18% |
| HDL Cholesterol | โ 12% |
| Systolic Blood Pressure | โ 7 mmHg |
Side Effects Observed in Trials
What researchers reported
Like other GLP-1 medications, the most common side effects were gastrointestinal in nature. Most were mild to moderate and occurred mainly during the dose escalation period, then improved.
This side effect is unique to Retatrutide and not commonly seen with other GLP-1 medications. It's likely related to the glucagon receptor activity.
- Described as tingling, burning, or numbness sensations
- Usually mild and temporary
- 20.9% at 12mg vs 0.7% on placebo
- May be caused by glucagon receptor's effect on nerves
| 12mg | 18.2% |
| 9mg | 12.2% |
| 4mg | 6.8% |
| Placebo | 4.0% |
- These rates are at the 12mg dose โ lower doses had fewer side effects.
- Most GI side effects improve after the first 4โ8 weeks as the body adjusts.
Compound Information
Technical specifications
| Type | Synthetic peptide |
| CAS Number | 2381089-83-2 |
| Molecular Weight | 4,731 g/mol |
| Amino Acids | 39 |
| Fatty Acid Chain | C20 diacid |
| Developer | Eli Lilly |
| Trial Program | TRIUMPH |
| Phase 3 Results | Expected 2026 |
| Potential Approval | ~2027 |
Frequently Asked Questions
Common questions about Retatrutide research
Sources & References
Peer-reviewed research
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.